Anúncio
Anúncio

ATXS

ATXS logo

Astria Therapeutics, Inc. Common Stock

12.88
USD
Patrocinado
-0.09
-0.72%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pré-Mercado

12.98

+0.10
+0.81%

Relatórios de Lucros ATXS

Rácio de surpresa positiva

ATXS separação 24 de 40 últimas estimativas.

60%

Próximo Relatório

Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$3.06M
/
-$0.56
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+333.43%
/
+1.82%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
+180.00%

Astria Therapeutics, Inc. Common Stock earnings per share and revenue

On 12 de nov. de 2025, ATXS reported earnings of -0.55 USD per share (EPS) for Q3 25, missing the estimate of -0.39 USD, resulting in a -38.12% surprise. Revenue reached 706.00 mil, compared to an expected 10.88 milhão, with a -93.51% difference. The market reacted with a +0.32% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analistas forecast an EPS of -0.56 USD, with revenue projected to reach 3.06 milhão USD, implying an aumentar of 1.82% EPS, and aumentar of 333.43% in Revenue from the last quarter.
FAQ
For Q3 2025, Astria Therapeutics, Inc. Common Stock reported EPS of -$0.55, missing estimates by -38.12%, and revenue of $706.00K, -93.51% below expectations.
The stock price moved up 0.32%, changed from $12.51 before the earnings release to $12.55 the day after.
The next earning report is scheduled for 09 de mar. de 2026.
Based on 9 analistas, Astria Therapeutics, Inc. Common Stock is expected to report EPS of -$0.56 and revenue of $3.06M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio